Technical Analysis for HGEN - Humanigen Inc.

Grade Last Price % Change Price Change
F 13.54 -2.52% -0.3500
HGEN closed down 2.52 percent on Tuesday, April 20, 2021, on 47 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical HGEN trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 200 DMA Bearish -2.52%
Wide Bands Range Expansion -2.52%
Gapped Down Weakness -2.52%
Oversold Stochastic Weakness -2.52%
Narrow Range Bar Range Contraction -8.08%
Wide Bands Range Expansion -8.08%
Older End-of-Day Signals for HGEN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2% 8 days ago
Down 1% 8 days ago
Up 2% 8 days ago
Up 1% 8 days ago
Bearish 180 Entry 8 days ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Humanigen Inc. Description

Humanigen, Inc., a biopharmaceutical company, engages in developing its proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's products include lenzilumab and ifabotuzumab, which are monoclonal antibodies derived from Humaneered platform. Lenzilumab targets granulocyte-macrophage colony-stimulating factor (GM-CSF), and is in development as a potential medicine for chimeric antigen receptor T cell (CAR-T) therapy, as well as a potential treatment for rare hematologic cancers, such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Ifabotuzumab targets Ephrin type-A receptor 3 (EphA3), and is being explored as a potential treatment for glioblastoma multiforme (GBM) and other cancers, as well as for use in novel CAR-T construct and bispecific antibody platform. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Medical Specialties Clinical Medicine Biopharmaceutical Immune System Antibodies Cancers Antigen Cancer Immunotherapy Immunotherapy Stoma Monoclonal Antibodies Leukemia T Cell Blastoma Lomo Gen Re Glioblastoma Chime Chimeric Antigen Receptor T Cell Glioblastoma Multiforme Hematologic Cancers

Is HGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 33.95
52 Week Low 1.5
Average Volume 3,241,255
200-Day Moving Average 14.4732
50-Day Moving Average 17.5780
20-Day Moving Average 16.3795
10-Day Moving Average 15.4990
Average True Range 1.8227
ADX 18.48
+DI 25.5530
-DI 28.1470
Chandelier Exit (Long, 3 ATRs ) 23.7319
Chandelier Exit (Short, 3 ATRs ) 17.8291
Upper Bollinger Band 21.4184
Lower Bollinger Band 11.3406
Percent B (%b) 0.22
BandWidth 61.5269
MACD Line -0.8056
MACD Signal Line -0.4358
MACD Histogram -0.3699
Fundamentals Value
Market Cap 698.89 Million
Num Shares 51.6 Million
EPS -0.09
Price-to-Earnings (P/E) Ratio -147.17
Price-to-Sales 0.00
Price-to-Book 15.12
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.6050
Resistance 3 (R3) 14.6333 14.3067 14.4275
Resistance 2 (R2) 14.3067 14.0354 14.2925 14.3683
Resistance 1 (R1) 13.9233 13.8679 13.7600 13.8950 14.3091
Pivot Point 13.5967 13.5967 13.5150 13.5825 13.5967
Support 1 (S1) 13.2133 13.3254 13.0500 13.1850 12.7709
Support 2 (S2) 12.8867 13.1579 12.8725 12.7117
Support 3 (S3) 12.5033 12.8867 12.6525
Support 4 (S4) 12.4750